{"title":"Transcatheter annuloplasty with the K-Clip system for tricuspid regurgitation: one-year results from the TriStar study.","authors":"Xiaochun Zhang, Qinchun Jin, Wei Li, Cuizhen Pan, Kefang Guo, Xue Yang, Weidong Li, Guangyuan Song, Jiangfang Luo, Jie Li, Xianbao Liu, Shasha Chen, Lei Zhang, Dandan Chen, Shiqiang Hou, Juying Qian, Jianan Wang, Daxin Zhou, Junbo Ge","doi":"10.4244/EIJ-D-24-00591","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Despite the fact that morbidity and mortality rates significantly increase with tricuspid regurgitation (TR) severity, limited treatment options are available for treating severe TR.</p><p><strong>Aims: </strong>The single-arm, multicentre, prospective Confirmatory Clinical Study of Treating Tricuspid Regurgitation With K-Clip TM Transcatheter Annuloplasty System (TriStar) evaluated the 1-year outcomes of the novel transcatheter K-Clip annuloplasty system in treating secondary TR.</p><p><strong>Methods: </strong>Between May 2022 and October 2022, patients with ≥severe secondary TR despite optimal medical therapy at 11 centres in China were deemed candidates for transcatheter tricuspid repair by the local Heart Team and a multidisciplinary screening committee. Echocardiographic parameters, clinical and quality-of-life measures, and major adverse events were collected at 1 year.</p><p><strong>Results: </strong>Ninety-six patients were enrolled (mean age 72.6±7.0 years, 60.4% female, mean TRI-SCORE 5.4±2.1). The technical success rate was 97.9%. At 1 year, echocardiographic follow-up showed an average reduction in the annular septolateral diameter of 11.3% (41.9 mm vs 37.1 mm; p<0.01), compared with baseline, with marked right ventricular remodelling. A total of 82.5% of patients had ≤moderate TR, and 97.7% had a ≥1 grade reduction. Patients experienced significant clinical improvements in New York Heart Association Functional Class I/II (32.6% to 96.5%; p<0.001), the 6-minute walk distance increased by 31.9±71.8 m (p<0.001), and the overall Kansas City Cardiomyopathy Questionnaire score increased by 7.6±17.7 points (p<0.001). Neither cardiovascular death nor reintervention were recorded at the 30-day or 1-year follow-up, while severe bleeding requiring further treatment was noted in 5 patients at 1 year. The Kaplan-Meier estimates of survival and freedom from heart failure rehospitalisation were 97.8% and 95.1%, respectively, at 1 year.</p><p><strong>Conclusions: </strong>The 1-year experience using the K-Clip tricuspid annuloplasty system demonstrated high survival and low rehospitalisation rates with durable TR reduction and clinical benefits in functional status and quality-of-life outcomes.</p>","PeriodicalId":54378,"journal":{"name":"Eurointervention","volume":"21 5","pages":"e262-e271"},"PeriodicalIF":9.5000,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11849535/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Eurointervention","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.4244/EIJ-D-24-00591","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Despite the fact that morbidity and mortality rates significantly increase with tricuspid regurgitation (TR) severity, limited treatment options are available for treating severe TR.
Aims: The single-arm, multicentre, prospective Confirmatory Clinical Study of Treating Tricuspid Regurgitation With K-Clip TM Transcatheter Annuloplasty System (TriStar) evaluated the 1-year outcomes of the novel transcatheter K-Clip annuloplasty system in treating secondary TR.
Methods: Between May 2022 and October 2022, patients with ≥severe secondary TR despite optimal medical therapy at 11 centres in China were deemed candidates for transcatheter tricuspid repair by the local Heart Team and a multidisciplinary screening committee. Echocardiographic parameters, clinical and quality-of-life measures, and major adverse events were collected at 1 year.
Results: Ninety-six patients were enrolled (mean age 72.6±7.0 years, 60.4% female, mean TRI-SCORE 5.4±2.1). The technical success rate was 97.9%. At 1 year, echocardiographic follow-up showed an average reduction in the annular septolateral diameter of 11.3% (41.9 mm vs 37.1 mm; p<0.01), compared with baseline, with marked right ventricular remodelling. A total of 82.5% of patients had ≤moderate TR, and 97.7% had a ≥1 grade reduction. Patients experienced significant clinical improvements in New York Heart Association Functional Class I/II (32.6% to 96.5%; p<0.001), the 6-minute walk distance increased by 31.9±71.8 m (p<0.001), and the overall Kansas City Cardiomyopathy Questionnaire score increased by 7.6±17.7 points (p<0.001). Neither cardiovascular death nor reintervention were recorded at the 30-day or 1-year follow-up, while severe bleeding requiring further treatment was noted in 5 patients at 1 year. The Kaplan-Meier estimates of survival and freedom from heart failure rehospitalisation were 97.8% and 95.1%, respectively, at 1 year.
Conclusions: The 1-year experience using the K-Clip tricuspid annuloplasty system demonstrated high survival and low rehospitalisation rates with durable TR reduction and clinical benefits in functional status and quality-of-life outcomes.
背景:尽管发病率和死亡率随着三尖瓣反流(TR)严重程度的增加而显著增加,但治疗严重TR的治疗方案有限。目的:单臂、多中心、前瞻性的K-Clip TM经导管环成形术治疗三尖瓣反流的临床验证研究(TriStar)评估了新型经导管K-Clip环成形术治疗继发性TR的1年疗效。在2022年5月至2022年10月期间,尽管在中国11个中心接受了最佳药物治疗,但仍有≥严重继发性TR的患者被当地心脏团队和多学科筛查委员会视为经导管三尖瓣修复的候选人。1年时收集超声心动图参数、临床和生活质量指标以及主要不良事件。结果:96例患者入组(平均年龄72.6±7.0岁,女性60.4%,TRI-SCORE平均值5.4±2.1)。技术成功率97.9%。1年后,超声心动图随访显示中隔环直径平均减少11.3% (41.9 mm vs 37.1 mm;结论:使用K-Clip三尖瓣环成形术系统的1年经验表明,生存率高,再住院率低,持久的TR降低,在功能状态和生活质量方面的临床益处。
期刊介绍:
EuroIntervention Journal is an international, English language, peer-reviewed journal whose aim is to create a community of high quality research and education in the field of percutaneous and surgical cardiovascular interventions.